NASDAQ:PRTA Prothena Q2 2026 Earnings Report $9.39 -0.06 (-0.63%) Closing price 08/24/2026 04:00 PM EasternExtended Trading$9.35 -0.04 (-0.43%) As of 08:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Prothena EPS ResultsActual EPS-$0.32Consensus EPS -$0.39Beat/MissBeat by +$0.07One Year Ago EPSN/AProthena Revenue ResultsActual Revenue$1.01 millionExpected Revenue$0.42 millionBeat/MissBeat by +$588.00 thousandYoY Revenue GrowthN/AProthena Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time4:00PM ETUpcoming EarningsProthena's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Prothena Earnings HeadlinesProthena (NASDAQ:PRTA) Stock Crosses Below 200-Day Moving Average - Here's What HappenedAugust 19, 2026 | americanbankingnews.comRBC Capital Keeps Their Hold Rating on Prothena (PRTA)August 8, 2026 | theglobeandmail.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.August 25 at 1:00 AM | Banyan Hill Publishing (Ad)Prothena: Q2 Earnings SnapshotAugust 6, 2026 | chron.comProthena Reports Second Quarter 2026 Financial Results and Business HighlightsAugust 6, 2026 | businesswire.comProthena to Report Second Quarter 2026 Financial Results on August 6July 30, 2026 | finance.yahoo.comSee More Prothena Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prothena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prothena and other key companies, straight to your email. Email Address About ProthenaProthena (NASDAQ:PRTA) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages. The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials. Additional pipeline candidates include therapies for amyloid light chain (AL) amyloidosis and other protein misfolding disorders. Prothena collaborates with global pharmaceutical partners to further develop and commercialize its product candidates, pooling resources and expertise to accelerate research timelines. Founded in 2012 as a spin-out from Elan Corporation, Prothena is headquartered in South San Francisco, California, with research operations in both the United States and Ireland. The company maintains a global focus, engaging regulators and trial sites across North America, Europe and Asia to support its clinical development programs. Prothena’s commitment to addressing high-unmet-need diseases is reflected in its strategic partnerships and research investments. Prothena is led by President and Chief Executive Officer Gene Kinney, whose experience spans decades in the pharmaceutical and biotechnology sectors. Under his leadership, the company has built a multidisciplinary team of scientists, clinicians and commercial experts. Prothena’s board and management team bring deep expertise in protein science, immunology and drug development to guide the company’s mission of bringing new treatment options to patients worldwide. View Prothena ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The Bull Case for D-Wave After a Disappointing Earnings SeasonVisa Just Put Hims & Hers in the Penalty Box—Here’s Why It MattersMongoDB Is Surging—And the Next Catalyst Is Almost Here5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here's WhyMarketBeat Week in Review – 08/17 - 08/21BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish SetupFlash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch Upcoming Earnings Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026)Autodesk (8/27/2026)Marvell Technology (8/27/2026)Medtronic (9/1/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
